A short review on antibody therapy for COVID-19

被引：44
作者：
Kumar, G. Venkat [1 ]
Jeyanthi, V [2 ]
Ramakrishnan, S. [3 ]
机构：
[1] Ponnaiyah Ramajayam Inst Sci & Technol, Dept Biotechnol, Thanjavur 613403, Tamil Nadu, India
[2] SRM Arts & Sci Coll, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India
[3] NCI, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA
来源：
NEW MICROBES AND NEW INFECTIONS | 2020年 / 35卷
关键词：
Convalescent plasma therapy; monoclonal antibody therapy; receptor binding domain; SARS-CoV-2; spike protein; CONVALESCENT PLASMA; SARS CORONAVIRUS; SPIKE; PROTEIN; BINDING;
D O I：
10.1016/j.nmni.2020.100682
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页数：4
相关论文
共 35 条
  • [1] The proximal origin of SARS-CoV-2
    Andersen, Kristian G.
    Rambaut, Andrew
    Lipkin, W. Ian
    Holmes, Edward C.
    Garry, Robert F.
    [J]. NATURE MEDICINE, 2020, 26 (04) : 450 - 452
  • [2] Convalescent plasma therapy for persistent hepatitis E virus infection
    Ankcorn, Michael
    Gallacher, Jennifer
    Ijaz, Samreen
    Taha, Yusri
    Harvala, Heli
    Maclennan, Sheila
    Thomson, Emma C.
    Davis, Chris
    Singer, Joshua B.
    Filipe, Ana da Silva
    Smollett, Katherine
    Niebel, Marc
    Semple, Malcolm G.
    Tedder, Richard S.
    McPherson, Stuart
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 434 - 438
  • [3] [Anonymous], 2020, CORONAVIRUS COVID 19
  • [4] [Anonymous], EFFICACY HYDROXYCHLO, DOI 10.1101/2020.03.22.20040758
  • [5] Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians
    Arabi, Yaseen M.
    Al-Enezi, Farhan
    Longuere, Kajsa-Stina
    Balkhy, Hanan H.
    Al-Sultan, Mohamed
    Al-Omari, Awad
    Al-Hameed, Fahad M.
    Carson, Gail
    Shindo, Nahoko
    Fowler, Robert
    [J]. BMC ANESTHESIOLOGY, 2016, 16
  • [6] The convalescent sera option for containing COVID-19
    Casadevall, Arturo
    Pirofski, Liise-Anne
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) : 1545 - 1548
  • [7] Chen J, 2020, J ZHEJIANG U MED SCI, V49
  • [8] Convalescent plasma as a potential therapy for COVID-19
    Chen, Long
    Xiong, Jing
    Bao, Lei
    Shi, Yuan
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (04) : 398 - 400
  • [9] Use of convalescent plasma therapy in SARS patients in Hong Kong
    Cheng, Y
    Wong, R
    Soo, YOY
    Wong, WS
    Lee, CK
    Ng, MHL
    Chan, P
    Wong, KC
    Leung, CB
    Cheng, G
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) : 44 - 46
  • [10] Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study
    Chowell, Gerardo
    Abdirizak, Fatima
    Lee, Sunmi
    Lee, Jonggul
    Jung, Eunok
    Nishiura, Hiroshi
    Viboud, Cecile
    [J]. BMC MEDICINE, 2015, 13
1234